GlaxoSmithKline invested milions of dollars into research of cardarine aka gw501516 and then abandoned it in phase 2 because it showed that the drug caused cancer to develop rapidly in several organs, at dosages of 3 mg/kg in mice and rats.
In 2013, WADA took the rare step of warning potential...